Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Akari Therapeutics Plc Is An Oncology Company Developing Next-Generation Antibody-Drug Conjugates (Adcs) Built Around Novel, Proprietary Payloads Utilizing Powerful Biology To Attack Cancer. Its Payload, Ph1, Targets Rna Splicing By Modulating The Spliceosome, A Complex Machinery In The Cell That Converts Pre-Rna Into Spliced Rna For Translation Into Vital Proteins For Cell Survival And Growth. Its Product Pipeline Is Aktx-101, Which Targets The Trop2 Receptor On Cancer Cells And, With A Proprietary Linker, Enables It To Deliver Its Novel Ph1 Payload Directly Into The Tumor With Minimal Off-Target Effects. And Aktx-102, An Adc Candidate Targeting Ceacam5 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule-5), A Well-Validated Tumor Antigen Expressed Across Multiple Solid Tumors.